P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY

• LI Zhi-Ming,
• Peng Sun,
• Hong Cen,
• Hai-Yan Yang,
• Rui Huang,
• Zhen Cai,
• Xue-Kui Gu

Affiliations

LI Zhi-Ming

1 Sun Yat-sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Peng Sun

1 Sun Yat-sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Hong Cen

2 Guangxi Medical University Affiliated Tumor Hospital, Department of Lymphohematology and Pediatric Oncology, Nanning, China

Hai-Yan Yang

3 Zhejiang Cancer Hospital, Department of Lymphoma, China

Rui Huang

4 Zhujiang Hospital of Southern Medical University, Department of Hematology, China

Zhen Cai

5 The First Affiliated Hospital of Zhejiang University School of Medicine, Bone Marrow Transplantation Center of Hematology Department, China

Xue-Kui Gu

6 The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Department of Hematology, China